Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Yoder

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Annals of Surgical Oncology|April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast CancerPat Whitworth, Peter D Beitsch, James V Pellicane, et al.
JCO Precision Oncology|April 27, 2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene SignaturePat W Whitworth, Peter D Beitsch, James V Pellicane, et al.
Molecular Ecology|November 7, 2020
Sharing and reporting benefits from biodiversity researchEmily Marden, Richard J Abbott, Frédéric Austerlitz, et al.
Science (New York, N.Y.)|March 17, 2022
Global urban environmental change drives adaptation in white cloverJames S Santangelo, Rob W Ness, Beata Cohan, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Annals of Surgical Oncology|April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast CancerPat Whitworth, Peter D Beitsch, James V Pellicane, et al.
JCO Precision Oncology|April 27, 2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene SignaturePat W Whitworth, Peter D Beitsch, James V Pellicane, et al.
Molecular Ecology|November 7, 2020
Sharing and reporting benefits from biodiversity researchEmily Marden, Richard J Abbott, Frédéric Austerlitz, et al.
Science (New York, N.Y.)|March 17, 2022
Global urban environmental change drives adaptation in white cloverJames S Santangelo, Rob W Ness, Beata Cohan, et al.
Pageof 8